Clinical Trial: Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Major Depressive Disorder
Study Type: INTERVENTIONAL
Official Title: A Randomized, Double-Blind, Placebo-Controlled Trial of Solriamfetol in Subjects With Major Depressive Disorder
Brief Summary:
PARADIGM (Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the safety and efficacy of solriamfetol for the treatment of major depressive disorder (MDD) in adults.
Read more